Prostate Cancer Clinical Trials in Baltimore

Showing 181-200 of 388 trials

TERMINATEDPhase 1< 1 mile

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

NCT03619655

The study is an open label, non-randomized study designed to evaluate the diagnostic performance of SPECT CT.

Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3 participantsStarted Nov 2019

Baltimore, Maryland, United States • Philadelphia, Pennsylvania, United States

COMPLETEDNA< 1 mile

Behavioral Weight Loss Program for Cancer Survivors in Maryland

NCT04534309

Behavioral Weight Loss for Overweight and Obese Cancer Survivors in Maryland: A Demonstration Project

Breast CancerProstate CancerMelanoma (Skin)+5 more

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins340 participantsStarted Sep 2020

Baltimore, Maryland, United States

COMPLETEDPhase 1/2< 1 mile

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

NCT01485861

This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of apitolisib administrated in combination with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus placebo with abiraterone and prednisone/prednisolone and a safety single-arm, open-label cohort of ipatasertib 400 mg daily alone or in combination with prednisone/prednisolone or prednisone/prednisolone plus abiraterone.

Prostate Cancer

Genentech, Inc.298 participantsStarted Jan 2012

Scottsdale, Arizona, United States • San Francisco, California, United States • Fort Myers, Florida, United States +56 more locations

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

Behavioral Weight Loss Program for Cancer Survivors in Maryland

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Prostate Cancer Trials in Other Cities

A Study of FT-7051 in Men With MCRPC

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

A Study of PRT2527 in Participants With Advanced Solid Tumors

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Pioneering Advances in Care and Education (PACE)

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform

Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Telomere Associated Variables (TAVs) in Prostate Cancer

Other Conditions in Baltimore